Drug Profile
Research programme: chimeric antigen receptor T-cell therapies - Precision Biosciences/Servier
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Baxalta; Precision Biosciences
- Developer Precision Biosciences; Servier
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (IV)
- 03 Feb 2021 Preclinical development in Haematological malignancies is still ongoing in USA (IV) (Precision Biosciences' pipeline, February 2021)
- 03 Feb 2021 Preclinical trials in Solid tumours in USA (IV) before February 2021 (Precision Biosciences' pipeline, February 2021)